An expanded-access program to investigate PLX-PAD in patients with Critical Limb Ischemia (CLI)

Trial Profile

An expanded-access program to investigate PLX-PAD in patients with Critical Limb Ischemia (CLI)

Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs PLX PAD (Primary)
  • Indications Peripheral arterial disorders
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 09 Jan 2018 According to a Pluristem Therapeutics media release, the US FDA has cleared the Company's Expanded Access Program (EAP) for the use of its PLX-PAD cell treatment in patients with Critical Limb Ischemia (CLI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top